Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Cancer has traditionally been a spiraling disease involving life or death decisions against a backdrop of limited understanding of the disease mechanism, diagnosis, uncertainties related to treatment outcome, and cost associated with the diagnosis and treatment. In recent years however, the underlying biology of specific tumor types is been unraveling mostly because of a better understanding of the genetic makeup of the tumor, and its impact for an individual patient. An exciting ongoing development is the field of tumor immunology leading to innovative therapeutic approaches by activating a patient’s immune system in the fight to stop and ultimately eliminate the malignant growth.

The increase in our genetics knowledge and the emerging understanding of an individual’s response to established tumors allows a physician to tackle cancer in a patient-centered way as opposed to a traditional disease category centered treatment. This includes improved personalized screening and risk assessment options, tailored cancer treatments, improved pharmacogenomics which takes the drug response into account. However in spite of the promises of personalized cancer treatments, many challenges remain to be overcome. Doctors and patients may not have all critical information (e.g. genetic insights) at their fingertips to most effectively translate the recent scientific advances into tangible treatment plans, and cost considerations related to genetic testing and treatment need to be part of the equation for successful solutions.  

Come join the 10th Personalized Medicine World Conference on January 24-27and hear first-hand from leading oncologist and researchers at top medical institutions presenting their work and research (e.g. stem cell research), including new approaches for clinical trials, novel therapeutic strategies to enhance anti-tumor immunity, and new cancer screening practices (e.g. breast cancer screening), and their approaches to stay up-to-date and be informed about the options a physician and patient has in today’s healthcare environment.


Peter Bach, M.D., MAPP, Director, Center for Health Policy & Outcomes, Memorial Sloan Kettering

The Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, Dr. Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. Read Full Bio

Maximilian Diehn, M.D., Ph.D., Assistant Professor, Stanford University School of Medicine

Max Diehn MD, PhD is an Assistant Professor of Radiation Oncology at Stanford University. He has co-appointments in the Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine. Dr. Diehn trained at Harvard University and Stanford University and has a background in genomics and stem cell biology. Read Full Bio


Laura Esserman, M.D., M.B.A, Director, Carol Franc Buck Breast Care Center, Professor of Surgery and Radiology, University of California, San Francisco, Associate Director, UCSF Helen Diller Family Comprehensive Cancer Center

aura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment. Since 2002 she has led the I-SPY TRIALS, a groundbreaking national public-private collaboration among NCI, FDA, more than 20 cancer research centers and major pharma and biotech companies. Read Full Bio


Holbrook E.K. Kohrt, M.D., Ph.D., Divisions of Hematology and Oncology, Stanford University Medical Center

Dr. Kohrt currently investigates novel therapeutic strategies to enhance anti-tumor immunity, including discovery of checkpoint inhibitors and cancer vaccine strategies. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar and American Society of Hematology Research Fellow. Read Full Bio


  • Impact of Patient Data Access on Oncology Precision Medicine
  • Cancer Diagnostics
  • Healthcare Information and Management Systems
  • The Role of Practicing Pathologists in Personalized Medicine
  • New Drug Discovery in Oncology: Faster, Cheaper and Better
Web Analytics